Article
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Feb 2013
Kim Kevin B, Kefford Richard, Pavlick Anna C, Infante Jeffrey R, Ribas Antoni, Sosman Jeffrey A, Fecher Leslie A, Millward Michael, McArthur Grant A, Hwu Patrick, Gonzalez Rene, Ott Patrick A, Long Georgina V, Gardner Olivia S, Ouellet Daniele, Xu Yanmei, DeMarini Douglas J, Le Ngocdiep T, Patel Kiran, Lewis Karl D
Abstract excerpt
PURPOSE: BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose of this study was to determine the response rate (RR) for the selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with metastatic BRAF-mutant melanoma. PATIENTS AND METHODS: This was an open-label, two-stage, phase II study with two cohorts. Patients with metastatic...
Topics
Join the communities discussing this publication.